Edition:
India

SSY Group Ltd (2005.HK)

2005.HK on Hong Kong Stock

8.92HKD
20 Jun 2018
Change (% chg)

HK$0.32 (+3.72%)
Prev Close
HK$8.60
Open
HK$8.51
Day's High
HK$9.13
Day's Low
HK$8.51
Volume
11,187,591
Avg. Vol
9,076,552
52-wk High
HK$9.46
52-wk Low
HK$2.98

Latest Key Developments (Source: Significant Developments)

SSY Group Updates On Product Approval
Monday, 4 Jun 2018 

June 4 (Reuters) - SSY Group Ltd <2005.HK>::OBTAINED APPROVALS FOR DRUG PRODUCTION & REGISTRATION FOR POTASSIUM CHLORIDE INJECTION FROM CHINA FOOD AND DRUG ADMINISTRATION.  Full Article

SSY Group Obtained Approvals For Drug Production And Registration From China FDA
Tuesday, 24 Apr 2018 

April 24 (Reuters) - SSY Group Ltd <2005.HK>::OBTAINED APPROVALS FOR DRUG PRODUCTION AND REGISTRATION FOR BALANCED SALT SOLUTION (IRRIGATING) (250ML AND 500ML) FROM CHINA FDA.  Full Article

SSY Group Ltd Posts Qtrly Turnover Of About Hk$1.10 Bln
Monday, 16 Apr 2018 

April 16 (Reuters) - SSY Group Ltd <2005.HK>::QTRLY TURNOVER INCREASED BY 74% AS COMPARED WITH SAME PERIOD OF 2017 TO ABOUT HK$1,099 MILLION.QTRLY UNAUDITED PROFIT ATTRIBUTABLE TO SHAREHOLDERS OF CO HK$242 MILLION, UP 111%.  Full Article

SSY Group Posts FY Net Profit Of HK$665 Mln, Up 35.8 Pct
Tuesday, 27 Mar 2018 

March 27 (Reuters) - Ssy Group Ltd <2005.HK>::BOARD RESOLVED TO PAY A FINAL DIVIDEND OF HK$0.04 PER SHARE FOR YEAR ENDED 31 DECEMBER 2017.FY REVENUE OF HK$3,076 MILLION, UP 30.3 PCT.FY NET PROFIT OF HK$665 MILLION, UP 35.8 PCT.  Full Article

SSY Group Updates on Product Development
Monday, 11 Dec 2017 

Dec 11 (Reuters) - SSY Group Ltd <2005.HK>::SSY GROUP-OBTAINED APPROVAL FOR DRUG PRODUCTION & REGISTRATION FOR SODIUM ACETATE RINGER'S INJECTION (500ML) FROM CHINA FOOD & DRUG ADMINISTRATION​.  Full Article

SSY Group says turnover of group for 9 months ended Sept. 30, 2017, HK$2,105 mln, up 24.2 pct
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - SSY Group Ltd <2005.HK>::‍Gross profit margin of group for nine months ended Sept. 30, 2017 was 55.1​ percent, up 4.4 percent.‍Turnover of group for nine months ended 30 september 2017 is HK$2,105 million, up by 24.2 percent​.  Full Article

SSY Group obtains approval for drug clinical trial from China FDA<2005.HK>
Wednesday, 31 Aug 2016 

SSY Group Ltd <2005.HK>: Voluntary announcement - update on product development <2005.HK> . Obtained approvals for drug registration and drug clinical trial for Trelagliptin Succinate bulk pharmaceutical and tablets respectively . Obtained approvals for drug clinical trial for Ambroxol Hydrochloride solution for inhalation from the China Food and Drug Administration . Approval from the China Food and Drug Administration .  Full Article

SSY Group reports HY net profit HK$210 mln representing a decrease of 16.0%<2005.HK>
Tuesday, 30 Aug 2016 

SSY Group Ltd <2005.HK>: In the first half of this year, the group achieved a sales revenue of HK$1.11 billion representing an increase of 4.5% . Says directors resolved to pay an interim dividend of HK2.5 cents per share .Says HY net profit was HK$210 mln representing a decrease of 16.0%.  Full Article

SSY Group receives approval for certain products<2005.HK>
Thursday, 14 Jul 2016 

SSY Group Ltd <2005.HK>: Voluntary announcement - update on product development . Obtained approval for drug production and registration for ambroxol hydrochloride and sodium chloride injection from China FDA .  Full Article

BRIEF-Ssy Group Unit ‍Entered Agreement With Zhengzhou University For Research Of New Liver Fibrosis​ Drug

* UNIT ‍ENTERED AGREEMENT WITH ZHENGZHOU UNIVERSITY IN RELATION TO RESEARCH AND DEVELOPMENT OF NEW DRUG USED FOR LIVER FIBROSIS​